One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Continued to advance three clinical programs in immune-mediated diseases: The Phase 3 ONWARD program for ESK-001 in moderate-to-severe plaque psoriasis consists of two parallel 24-week global Phase 3 ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

It is approved for use in rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and adults with chronic moderate-to-severe plaque psoriasis. In clinical ...

Medically reviewed by Casey Gallagher, MD Psoriasis of the hands and feet, known as palmoplantar psoriasis, is an inflammatory autoimmune disorder that causes scaly, itchy skin patches on the palms ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

Top line results for the Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies 2 in moderate to severe plaque psoriasis, are expected in Q4 2024. Top line results for the Phase 2b ANTHEM multicenter, ...

Stationary plaque psoriasis, which is usually a chronic ... The clinical severity of psoriasis Psoriasis is classified as mild, moderate, or severe. This classification takes account of the ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments," said Samit ...